Chad Robins

Chad Robins is the chief executive officer, co-founder and chairman of Adaptive Biotechnologies (Nasdaq: ADPT), a commercial-stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease. The company operates across two business segments: Minimal Residual Disease (MRD), with its industry leading clonoSEQ® franchise, and Immune Medicine, a drug and target discovery and data platform.

In 2019, Chad guided Adaptive through its initial public offering, which was one of the year’s most successful biotech IPOs. Under his leadership, Adaptive launched clonoSEQ®, the first and only FDA-authorized next-generation sequencing-based test to detect and monitor MRD in hematologic malignancies.

Chad has also propelled Adaptive into the burgeoning health tech space, bringing cloud computing and machine learning together with Adaptive’s technology to map the immune response of many diseases, resulting in unparalleled T-cell receptor biology data sets. This work fuels Adaptive’s Immune Medicine business, advancing differentiated targeted therapies in cancer and autoimmunity.

Chad actively engages in the biotech and health policy communities. He chairs the boards of AltPep—an amyloid platform focused on Alzheimer’s and Parkinson’s disease; and the Coalition for 21st Century Medicine (C21)—a CEO-led board focused on policy and market access for the diagnostics industry. Chad also serves on the boards Life Science Washington, where he was the former Chair, Washington Roundtable, Digital Biotechnologies, and Headlight.

Chad graduated with honors from Cornell University and obtained his MBA from The Wharton School at the University of Pennsylvania. Prior to Adaptive, Chad held executive-level positions in real estate, investment banking, private equity, and medical technology